Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
End Stage Renal Disease: early-phase trial registry
25 of 88 indexed End Stage Renal Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #156 of 28,707 conditions by registered trial count.
88 US clinical trials · 25 currently recruiting · #156 of 28,707 conditions by registered trial count
End Stage Renal Disease: 88 US clinical trials tracked, 25 recruiting.
End Stage Renal Disease is the subject of 88 registered US clinical trials on ClinicalTrials.gov, 25 of them currently open to new participants. 16 are in Phase 3-4 (later-stage) and 27 in Phase 1-2 (earlier-stage). The most active sponsor is Vanderbilt University, running 4 of these trials.
Enrollment posture brief
Registry condition end-stage-renal-disease
OPEN 25 | RECR 28% | LATE 16 | EARLY 27 | RANK #156 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Acne Scars (29% recruiting · 7 trials)
End Stage Renal Disease lists 25 open slots (28% of 88 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for End Stage Renal Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
End Stage Renal Disease is recruiting below its size-band peers.
25 of 88 indexed trials (28.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of End Stage Renal Disease trials is spread across many organizations.
Vanderbilt University accounts for 4 of 88 trials (4.5%). 69 distinct sponsors appear on at least one study for this condition label.
-
Typical End Stage Renal Disease enrolment sits around 69 participants.
Median target enrolment is 69 among the 87 trials that report a genuine target (sentinel values excluded). 50 of those (57.5%) plan for fewer than 100 participants.
-
End Stage Renal Disease research is mostly interventional.
74 interventional and 14 observational studies make up this index (84.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
88 total, page 1 of 2
Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates
University of British Columbia
NCT03674307
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
VA Office of Research and Development
NCT05931276
Dissemination of the Donor Application: Utilizing Social Media to Identify Potential Live Organ Donors
Johns Hopkins University
NCT03803423
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
VenoStent
NCT06001827
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
Sonavex
NCT06190717
Partners Calciphylaxis Biobank
Massachusetts General Hospital
NCT03032835
Post Market Study for VasQ, an External Support Implant for Arteriovenous Fistula
Laminate Medical Technologies
NCT06516653
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
C. R. Bard
NCT04634916
CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease
Vanderbilt University Medical Center
NCT05422534
Drug Interaction Potential of Pro-Inflammatory Conditions
Indiana University
NCT07360938
PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis
Merit Medical Systems
NCT06422871
Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision
Hennepin Healthcare Research Institute
NCT05879302
Decellularized Femoral Artery Allograft (Nexeon AVX) Prospective Registry
LifeNet Health
NCT05880537
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
Roberto Gedaly
NCT03321656
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
VA Office of Research and Development
NCT04163614
Safety and Efficacy of Empagliflozin in Hemodialysis
NYU Langone Health
NCT05786443
Light Therapy in End Stage Kidney Disease
University of Pennsylvania
NCT06310161
Intravascular Ultrasound in Patients With End-stage Renal Disease on Dialysis
Boston Medical Center
NCT04399941
Solv Multi-Pass Hemodialysis System In-Center Clinical Study
Medtronic - MITG
NCT07216885
CAPABLE Transplant
Johns Hopkins University
NCT06326905
Tulane Abdominal Transplant Institute (TATI) of Solid Organ Transplantation of HIV-Positive Recipients From HIV-Positive Donors
Tulane University
NCT05159466
Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
NCT04580420
Oral Intradialytic Amino Acid Supplementation to Vitalize End-stage Kidney Disease Patients on Hemodialysis
The University of Texas Health Science Center at San Antonio
NCT05705414
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
Merck Sharp & Dohme
NCT07348237
AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses
Houssam Farres, M.D.
NCT04392206
Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure
Beth Israel Deaconess Medical Center
NCT02194582
Trial to Evaluate and Assess the Effect of Comprehensive Pre-ESKD Education on Home Dialysis Use in Veterans
VA Office of Research and Development
NCT04064086
VIRTUUS Children's Study
Children's Hospital of Philadelphia
NCT03719339
Increasing Live Donor Kidney Transplantation Through Video-based Education and Mobile Communication
State University of New York at Buffalo
NCT05154773
Communication During Hospitalization About Resuscitation Trial
University of Vermont
NCT02984124
Central Blood Pressure and Pulse Wave Velocity in Kidney Transplant Recipients
Children's National Research Institute
NCT04212143
Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)
Medtronic - MITG
NCT05696444
Ferric Citrate in ESRD Pilot Project
Sreedhar Mandayam
NCT03055598
One-month Latent Tuberculosis Treatment for Renal Transplant Candidates
Rutgers, The State University of New Jersey
NCT05411744
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
Stanley Jordan, MD
NCT03380962
Events Before Death
Renal Research Institute
NCT01329055
Inflammation and Nutritional Parameters in Hemodialysis Patients Using Reprocessed Dialyzers
Fresenius Medical Care North America
NCT00440908
Meals MATTER: A Trial of Medically Tailored Meals 2 Weeks vs. 4 Weeks Post Hospital Discharge
Kaiser Permanente
NCT04351880
Dialysis Catheter Comparative Clinical Trial
Tyco Healthcare Group
NCT00526123
Explore Transplant at Home: Improving Low-Income ESRD Patients' Transplant Knowledge
The Methodist Hospital Research Institute
NCT02268682
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)
Merck Sharp & Dohme
NCT05027074
Palm Tocotrienols in Chronic Hemodialysis (USA)
Wayne State University
NCT02358967
Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes
Vascular Therapies
NCT02513303
Phosphate Kinetic Modeling
Fresenius Medical Care North America
NCT01003223
Improved Induction and Maintenance Immunosuppression in Kidney Transplantation
University of Nebraska
NCT00556933
A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP
Ardelyx
NCT03988920
Protein, Nutrition and Cardiovascular Disease in Stage 5 Chronic Kidney Disease
University of Utah
NCT00566670
Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis
University of Washington
NCT03534284
Social Networks and Renal Education: Promoting Transplantation
Temple University
NCT03536858
Phase II Randomized Study of the Effects of Growth Hormone on Children and Adolescents on Maintenance Dialysis
National Center for Research Resources (NCRR)
NCT00004340
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 14 |
| Phase 3 | 7 |
| Phase 4 | 9 |
Top Sponsors
Named interventions
Most-linked intervention names on End Stage Renal Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on End Stage Renal Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this End Stage Renal Disease page
88 registered trials, 25 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 25 End Stage Renal Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Vanderbilt University sponsors the most End Stage Renal Disease trials on record, review their full trial history before evaluating a specific study. See Vanderbilt University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This End Stage Renal Disease condition card totals 88 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.